<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00055913</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02520</org_study_id>
    <secondary_id>NCI-2012-02520</secondary_id>
    <secondary_id>CDR0000271444</secondary_id>
    <secondary_id>UCCRC-NCI-5701</secondary_id>
    <secondary_id>UCCRC-11956A</secondary_id>
    <secondary_id>NCI-5701</secondary_id>
    <secondary_id>11956A</secondary_id>
    <secondary_id>5701</secondary_id>
    <secondary_id>P30CA014599</secondary_id>
    <secondary_id>N01CM62201</secondary_id>
    <nct_id>NCT00055913</nct_id>
  </id_info>
  <brief_title>Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer</brief_title>
  <official_title>A Phase I/II Study Of Bevacizumab (rhuMAb VEGF) In Combination With OSI-774 For Patients With Recurrent Or Metastatic Cancer Of The Head And Neck</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This randomized phase I/II trial is to see if combining erlotinib with bevacizumab works&#xD;
      better in treating patients who have recurrent or metastatic head and neck cancer. Erlotinib&#xD;
      may stop the growth of tumor cells by blocking the enzymes needed for tumor cell growth.&#xD;
      Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some&#xD;
      block the ability of cancer cells to grow and spread. Others find cancer cells and help kill&#xD;
      them or deliver cancer-killing substances to them. Combining erlotinib with bevacizumab may&#xD;
      kill more tumor cells.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose and dose-limiting toxicity of bevacizumab when&#xD;
      administered with erlotinib in patients with recurrent or metastatic head and neck cancer.&#xD;
&#xD;
      II. Determine the objective response rate and stable disease/absence of early progression in&#xD;
      patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study of bevacizumab followed by a randomized, multicenter&#xD;
      study.&#xD;
&#xD;
      Phase I: Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on&#xD;
      days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable&#xD;
      toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of bevacizumab until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      Phase II: Course 1 is 28 days in length. All subsequent courses are 21 days.&#xD;
&#xD;
      Course 1: Patients are randomized to 1 of 2 treatment arms.&#xD;
&#xD;
      Arm I: Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on&#xD;
      days 1-28.&#xD;
&#xD;
      Arm II: Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on&#xD;
      days 1-28.&#xD;
&#xD;
      All subsequent courses: All patients receive bevacizumab as in arm II and oral erlotinib on&#xD;
      days 1-21.&#xD;
&#xD;
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of bevacizumab when used in combination with erlotinib hydrochloride determined by dose-limiting toxicities (Phase I)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (CR + PR) evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) (Phase II)</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival rate (Phase II)</measure>
    <time_frame>Time from the start of treatment until disease progression or death, assessed up to 7 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall survival rate (Phase II)</measure>
    <time_frame>Up to 7 years</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Recurrent Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <condition>Salivary Gland Squamous Cell Carcinoma</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Hypopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Larynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Nasopharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Oropharynx</condition>
  <condition>Stage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on day 15 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bevacizumab IV over 30-90 minutes on day 1 and oral erlotinib on days 1-28. All subsequent courses patients receive oral erlotinib on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>bevacizumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>anti-VEGF humanized monoclonal antibody</other_name>
    <other_name>anti-VEGF monoclonal antibody</other_name>
    <other_name>Avastin</other_name>
    <other_name>rhuMAb VEGF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_label>Arm II</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed squamous cell cancer of the head and neck&#xD;
&#xD;
               -  Recurrent or metastatic disease&#xD;
&#xD;
               -  Determined to be incurable by surgery or radiotherapy&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
          -  No tumor involvement encasing or too close in proximity to a major artery or vein&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  No prior or concurrent CNS disease&#xD;
&#xD;
          -  No primary brain tumor&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 12 weeks&#xD;
&#xD;
          -  No history of bleeding diathesis&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  INR less than 1.5&#xD;
&#xD;
          -  Bilirubin normal&#xD;
&#xD;
          -  AST and ALT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No significant renal impairment&#xD;
&#xD;
          -  24-hour urinary protein less than 0.5 g required if more than trace proteinuria at&#xD;
             baseline&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No serious cardiac arrhythmia requiring medication&#xD;
&#xD;
          -  No deep venous thrombosis&#xD;
&#xD;
          -  No prior stroke&#xD;
&#xD;
          -  No New York Heart Association class II-IV heart disease&#xD;
&#xD;
          -  No grade II-IV peripheral vascular disease within the past year&#xD;
&#xD;
          -  No arterial thromboembolic event within the past 6 months, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Myocardial infarction&#xD;
&#xD;
               -  Transient ischemic attack&#xD;
&#xD;
               -  Cerebrovascular accident&#xD;
&#xD;
          -  No clinically significant peripheral artery disease&#xD;
&#xD;
          -  No significant ophthalmologic abnormalities* including any of the following:&#xD;
&#xD;
               -  Severe dry eye syndrome&#xD;
&#xD;
               -  Keratoconjunctivitis sicca&#xD;
&#xD;
               -  Sj√∂gren's syndrome&#xD;
&#xD;
               -  Severe exposure keratopathy&#xD;
&#xD;
               -  Disorders that might increase the risk for epithelium-related complications&#xD;
                  (e.g., bullous keratopathy, aniridia, severe chemical burns, neutrophilic&#xD;
                  keratitis)&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior allergic reactions to compounds of similar chemical or biologic composition&#xD;
             to bevacizumab or other study agents&#xD;
&#xD;
          -  No known hypersensitivity to Chinese hamster ovary cell products or other recombinant&#xD;
             human antibodies&#xD;
&#xD;
          -  No significant traumatic injury within the past 28 days&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No ongoing or active infection requiring parenteral antibiotics&#xD;
&#xD;
          -  No serious non-healing wound ulcer or bone fracture&#xD;
&#xD;
          -  No seizures not controlled by standard medical therapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
          -  More than 4 weeks since prior open biopsy&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  No more than 1 prior regimen for recurrent disease&#xD;
&#xD;
          -  No prior epidermal growth factor receptor (EGFR)-based therapy for recurrent disease&#xD;
&#xD;
          -  No prior vascular EGFR-based therapy for recurrent disease&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No concurrent chronic use of aspirin (325 mg/day or more) or other nonsteroidal&#xD;
             anti-inflammatory drugs&#xD;
&#xD;
          -  No concurrent warfarin or heparin, including low-molecular weight heparin&#xD;
&#xD;
          -  No other concurrent or recent (within 1 month) thrombolytic agents or full-dose&#xD;
             anticoagulants (except to maintain patency of preexisting, permanent indwelling IV&#xD;
             catheters)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanguy Seiwert</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>March 6, 2003</study_first_submitted>
  <study_first_submitted_qc>March 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2003</study_first_posted>
  <last_update_submitted>October 1, 2018</last_update_submitted>
  <last_update_submitted_qc>October 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 2, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Laryngeal Neoplasms</mesh_term>
    <mesh_term>Oropharyngeal Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
    <mesh_term>Paranasal Sinus Neoplasms</mesh_term>
    <mesh_term>Laryngeal Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Antineoplastic Agents, Immunological</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

